EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The Clinical Efficacy and Safety of ErhBMP ‐2/ BioCaP /β‐ TCP as a Novel Bone Substitute Using the Tooth‐Extraction‐Socket‐Healing Model: A Proof‐of‐Concept Randomized Controlled Trial

Lingfei Wei iD, Yuanyuan Sun, Dedong Yu, Herman Pieterse, Daniel Wismeijer, Yuelian Liu iD, Yiqun Wu

Journal of Clinical Periodontology · 2025-02 · 52 (2) · 299-309

DOI: 10.1111/jcpe.14084 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Periodontology, online erschienen am 31.10.2024. Verfasst von Lingfei Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Second Dental Center, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shang…. Hauptthemen laut MEDLINE: Calcium Phosphates, Bone Substitutes, Bone Morphogenetic Protein 2, Tooth Socket. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, ZonMW Project, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This first randomized controlled trial in humans aimed to assess the efficacy and safety of low‐dosage Escherichia coli ‐derived recombinant human bone morphogenetic protein 2 (ErhBMP‐2)‐incorporated biomimetic calcium phosphate coating‐functionalized β‐TCP (ErhBMP‐2/BioCaP/β‐TCP) as a novel bone substitute using the tooth‐extraction‐socket‐healing model. Materials and Methods Forty patients requiring dental implants after single‐root tooth extraction were enrolled in this study and randomly assigned into three groups: ErhBMP‐2/BioCaP/β‐TCP ( N = 15), β‐TCP ( N = 15) and natural healing ( N = 10). New bone volume density from histomorphometric analyses was evaluated 6 weeks post‐operatively as the primary outcome, and other histomorphometric analyses, alveolar bone and soft‐tissue changes were the secondary outcomes. Safety parameters included adverse events, soft‐tissue healing, oral health impact profile, serum BMP‐2 concentrations and other laboratory tests.

Results

The findings revealed a significant increase in new bone volume density in patients treated with ErhBMP‐2/BioCaP/β‐TCP compared to those receiving β‐TCP alone. The required bone augmentation procedures during implant placement surgery in the ErhBMP‐2/BioCaP/β‐TCP group were significantly less than in the natural healing group. There were no significant differences in safety parameters among the three groups.

Conclusion

This clinical trial primarily proved the safety and efficacy of ErhBMP‐2/BioCaP/β‐TCP as a promising bone substitute.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium PhosphatesBone SubstitutesBone Morphogenetic Protein 2Tooth SocketTooth ExtractionHumansMaleFemaleMiddle AgedWound HealingAdultTreatment OutcomeRecombinant ProteinsAgedProof of Concept StudyBone DensityCeramicsTransforming Growth Factor beta

Stichwörter der Autor:innen

biomimeticbone morphogenetic protein 2bone regenerationrandomized controlled trialtooth‐extraction‐socket healing

Substanzen

Calcium PhosphatesBone SubstitutesBone Morphogenetic Protein 2beta-tricalcium phosphateRecombinant Proteinsrecombinant human bone morphogenetic protein-2Transforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Second Dental Center, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Cl…
  • Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam and University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Oral Implantology, Yantai Stomatological Hospital, Binzhou Medical University, Yantai, China.
  • Profess Medical Consultancy BV, Heerhugowaard, The Netherlands.
  • TPE, Private Practice, Ellecom, The Netherlands.

ORCID-Profile: Lingfei Wei, Yuelian Liu

Förderung

  • National Natural Science Foundation of China
  • ZonMW Project
  • Natural Science Foundation of Shandong Province
  • Natural Science Foundation of Yantai
  • Shanghai Clinical Research Center for Oral Diseases
  • Shanghai Municipal Key Clinical Specialty
  • Shanghai's Top Priority Research Center
  • CAMS Innovation Fund for Medical Sciences (CIFMS)

Zitieren

APA

Wei, L., Sun, Y., Yu, D., Pieterse, H., Wismeijer, D., Liu, Y., & Wu, Y. (2025). The Clinical Efficacy and Safety of ErhBMP ‐2/ BioCaP /β‐ TCP as a Novel Bone Substitute Using the Tooth‐Extraction‐Socket‐Healing Model: A Proof‐of‐Concept Randomized Controlled Trial. Journal of Clinical Periodontology, 52(2), 299-309. https://doi.org/10.1111/jcpe.14084

Vancouver

Wei L, Sun Y, Yu D, Pieterse H, Wismeijer D, Liu Y, et al. The Clinical Efficacy and Safety of ErhBMP ‐2/ BioCaP /β‐ TCP as a Novel Bone Substitute Using the Tooth‐Extraction‐Socket‐Healing Model: A Proof‐of‐Concept Randomized Controlled Trial. Journal of Clinical Periodontology. 2025;52(2):299-309. doi:10.1111/jcpe.14084

BibTeX
@article{Wei2025,
  author = {Wei, Lingfei and Sun, Yuanyuan and Yu, Dedong and Pieterse, Herman and Wismeijer, Daniel and Liu, Yuelian and Wu, Yiqun},
  title = {The Clinical Efficacy and Safety of ErhBMP ‐2/ BioCaP /β‐ TCP as a Novel Bone Substitute Using the Tooth‐Extraction‐Socket‐Healing Model: A Proof‐of‐Concept Randomized Controlled Trial},
  journal = {Journal of Clinical Periodontology},
  year = {2025},
  volume = {52},
  number = {2},
  pages = {299--309},
  doi = {10.1111/jcpe.14084}
}
Kostenlos starten →